Cytological Biomarkers

Cytology have been act as a main tools utilised in the diagnosis of cancer. These techniques have evolved from an era of diagnosis based on haematoxylin and eosin (H&E) stained slides  to the current regular evaluation of tumours by immunocytochemistry (IHC) to confirm tumour histogenesis and subtype. In breast cancer, this means the routine IHC evaluation of hormone receptors (oestrogen and progesterone receptors) as well as evaluation of HER2 expression  and Ki67 (a marker of tumour proliferation). These factors strongly influence prognosis and the selection of anti-cancer treatments.

 

  • cytological carcinoma
  • Cytopathology marker

Related Conference of Cytological Biomarkers

March 18-19, 2024

5th Global Summit on Oncology and Hematology

Zurich, Switzerland
June 10-11, 2024

8th Global Meeting on Oncology and Radiology

Barcelona, Spain
July 11-12, 2024

24th World Congress on Cancer and Diagnostics

Vancouver, Canada
July 18-19, 2024

14th World Congress on Breast Cancer

Paris, France
September 19-20, 2024

25th World Congress on Cancer Summit

Paris, France

Cytological Biomarkers Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in